Tag Archives: Aducanumab (Biogen)

BBC iWonder Guide: How Close Are We to Stopping Alzheimer’s Disease? (BBC News)

Posted on November 27, 2016 by Dementia and Elderly Care News

Summary The BBC’s iWonder Guides provide “thought-provoking answers to the questions sparked by everyday life”. This particular collection of brief digestible articles, animations and videos covers: A frightening prospect (epidemiological statistics). How the disease affects your brain cells (an interactive … Continue reading →

Posted in Animal Studies, BBC News, In the News, Non-Pharmacological Treatments, Pharmacological Treatments, Quick Insights, Statistics, UK, Universal Interest | Tagged Aducanumab, Aducanumab (Biogen), Alzheimer’s Disease Clinical Trials, Amyloid, Amyloid Beta, Amyloid Beta Protein, Amyloid Proteins, Amyloid-Beta Clearance in Mice, Amyloid-Related Imaging Abnormalities (ARIA), Amyloid-Related Imaging Abnormalities-Edema/Effusion (ARIA-E), Anti-Amyloid-β (Aβ) Immunotherapy Trials, BBC Health News, BBC iWonder Guide on Alzheimer's Disease, BBC iWonder Guides, Brain Drain: Brain Glymphatic Transport, Brain Glymphatic System, Clearance of Amyloid Beta Protein, CNS Lymphatic System: Hypothesis Regarding Poor Sleep Patterns and Neuropathology, Dementia Prevalence, Drug Side-Effects, Drug Trials, Glymphatic System, iWonder Guides (BBC), Lifestyle Risk Factors, Misfolded Proteins, Modifiable Risk Factors, Need For Sleep, Neurofibrillary Tangles, Neurofibrillary Tangles (NFTs), Neuronal Loss, Neuropathological Features, Neuropathology, Neuroprotective Lifestyles, Prevention, Prevention Agenda, Prevention Approaches, Prevention of Dementia, Preventive Health, Professor Maiken Nedergaard: University of Copenhagen, Progression of Mild Cognitive Impairment to Dementia, Progression to Alzheimer's Disease, Reasons for Termination of Trials, Sleep Duration, Sleep Hygiene, Sleep Patterns, Sleeping Well, Tau Tangles, Therapeutic-Induced ARIA, Treatment Side-Effects: Therapeutic-Induced ARIA, University of Copenhagen | Leave a comment

Early Promising Signs in Verubecestat Human Drug Trial – Since Dashed (NHS Choices / Science Translational Medicine / Translational Neurodegeneration / Biospace Inc)

Posted on November 4, 2016 by Dementia and Elderly Care News

Summary Early results from a Phase I trial indicate that the BACE1 inhibitor Verubecestat may effectively reduce β-amyloid formation in human patients with Alzheimer’s Disease. This appears to confirm previous trials with rats, monkeys and healthy young human adults. As … Continue reading →

Early Signs of a Historic Breakthrough in the Treatment of Alzheimer’s Disease? (BBC News / Nature)

Posted on September 1, 2016 by Dementia and Elderly Care News

Summary Early results, based on small numbers of patients in a Phase I trial, indicate unprecedented progress in the development of a pharmacological treatment of Alzheimer’s Disease. The drug Aducanumab appears to combat (and reverse) the build-up of amyloid protein … Continue reading →

Posted in BBC News, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), In the News, International, Models of Dementia Care, Pharmacological Treatments, Quick Insights, Scotland, UK, Universal Interest | Tagged Aducanumab, Aducanumab (Biogen), Aducanumab: Recombinant Human Monoclonal Antibody, Aβ, Aβ Accumulation, Aβ-Plaques, Aβopathy, Amyloid Beta, Amyloid Beta Protein, Amyloid-β (Aβ), Amyloid-β Protein, Amyloidopathy, Antibody-Based Immunotherapy Against Aβ, BBC Health News, Beta-Amyloid, Beta-Amyloid Plaques, Biogen, Butler Hospital (USA), Centre for Cognitive and Neural Systems at the University of Edinburgh, Clinical Dementia Rating—Sum of Boxes, Disease-Modifying Therapies, Disease-Modifying Therapies for Dementia, Drug Side-Effects, Drugs for Cognitive Symptoms of Cognitive Decline and Dementia, Drugs for Treatment of Alzheimer’s Disease, Identification of People At Risk of Dementia, Institute for Regenerative Medicine: University of Zurich, International Collaborations, International Programmes, International Research, Intravenous Infusions of Aducanumab, β-Amyloid (Aβ) Accumulation, β-amyloid Deposition, Mini Mental State Examination (MMSE), Monoclonal Antibodies, Neurimmune (Switzerland), Neurodegeneration, Neurodegenerative Disease Research, Neurodegenerative Diseases, Neurodegenerative Disorders, Neurodegenerative Research, Neurofibrillary Tangles, Positron Emission Tomography (PET), Research and Development, Research and Innovation, Research Commitment, Slowing of Cognitive Decline, Susceptibility to Side-Effects of Medication, Switzerland, Treatment of Alzheimer's Disease, University College London, University of Edinburgh, University of Zurich | Leave a comment

New Drugs for Dementia (POST Note PN 535)

Posted on August 29, 2016 by Dementia and Elderly Care News

Summary The Parliamentary Office of Science and Technology (POST) has produced a briefing outlining some of the challenges in developing new drugs for dementia, explained in the context of ongoing UK and international research programmes. There is an extensive bibliography, … Continue reading →

Posted in Alzheimer's Society, Alzheimer’s Research UK, Antipsychotics, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), International, Models of Dementia Care, National, Pharmacological Treatments, Quick Insights, Statistics, UK, Universal Interest | Tagged Academic Institutes in the UK, Academy of Social Sciences, Aducanumab (Biogen), Alzheimer’s Association, Alzheimer’s Research UK’s Drug Discovery Alliance, Behavioural and Psychological Symptoms of Dementia (BPSD), Big Data, Big Data Funding and Research, Big Pharma, Biomarkers, Biomarkers Predicting Cognitive Decline and Alzheimer's Disease, BPSD: Behavioral and Psychological Symptoms of Dementia, British Psychological Society (BPS), Co-ordination and Data Analytics, Cognitive Health in Ageing Register for Investigations, Collaborative Projects, Collaborative Research, Dementia Consortium, Dementia Risk Prevention, Dementias Platform UK, Dementias Platform UK (DPUK), Dementias Platform UK: MRC, Disease Modifying Treatment by 2025 (Aim), Disease-Modifying Therapies, Disease-Modifying Therapies for Dementia, Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), DPUK: Dementias Platform UK, Drug Discovery Alliance, Drug Licensing Approval, Drugs for BPSD, Drugs for Cognitive Symptoms of Cognitive Decline and Dementia, EAMS: Early Access to Medicines Scheme, Early Access to Medicines Scheme, Effective Non-Drug Interventions, Etanercept, European Prevention of Alzheimer's Dementia Consortium (EPAD), European Prevention of Alzheimer’s Dementia Consortium, Identification of People At Risk of Dementia, International Collaborations, International Programmes, International Research, Join Dementia Research, Neurodegeneration, Neurodegenerative Disease Research, Neurodegenerative Diseases, Neurodegenerative Disorders, Neurodegenerative Research, New Drugs for Dementia (POST Note PN 535), NIHR Clinical Research Network, Observations & Trials in Dementia Research, Parliament, Parliamentary Office of Science & Technology, Parliamentary Office of Science & Technology (POST), Participation in Research, Patient Access to New Drugs, Pharmaceutical Industry, Pioglitazone, POST: Parliamentary Office of Science & Technology, Pre-Symptomatic Diagnosis of Dementia, Preclinical Biomarkers and Dementia, Preclinical Indicators and Dementia, Prevention, Public Participation in Research, Research and Development, Research and Innovation, Research Commitment, Research Culture, Research Mapping, Research Networks, Solanezumab (Eli Lilly), Symptom-Modifying Drugs for Dementia, UK Dementia Research Institute, UK Parliament, UK Patient Recruitment Initiatives, Verubecestat (Merck), Well-Being and Health for People With Dementia (WHELD) Program | Leave a comment

Tag Archives: Aducanumab (Biogen)

Early Promising Signs in Verubecestat Human Drug Trial – Since Dashed (NHS Choices / Science Translational Medicine / Translational Neurodegeneration / Biospace Inc)

Early Signs of a Historic Breakthrough in the Treatment of Alzheimer’s Disease? (BBC News / Nature)

Recent Posts

Archives

Categories

Google Translate (100+ Languages)

Recommended Sites